MEK Inhibition Aids in Serous Ovarian Cancer

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 05期
关键词：
D O I：
10.1158/2159-8290.CD-NB2012-029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a phase II trial of the experimental MEK inhibitor selumetinib (AZD6244), women who had failed 3 or more rounds of chemotherapy had 81% disease control and a median progression-free survival of 11.3 months.
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MEK inhibition for low-grade serous ovarian cancer: are we there yet?
    Scaranti, Mariana
    Mathias-Machado, Maria Cecilia
    Guo, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 155 - 156
  • [2] Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
    McNamara, Blair
    Demirkiran, Cem
    Hartwich, Tobias Max Philipp
    Bellone, Stefania
    Manavella, Diego
    Mutlu, Levent
    Greenman, Michelle
    Zipponi, Margherita
    Yang-Hartwich, Yang
    Yang, Kevin
    Ratner, Elena
    Schwartz, Peter E.
    Coma, Silvia
    Pachter, Jonathan A.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2024, 183 : 133 - 140
  • [3] Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors
    Kulkarni, Anjali
    Cooke, Carly
    Fazelzad, Rouhi
    Fung-Kee-Fung, Michael
    May, Taymaa
    Zigras, Tiffany
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (01): : 11 - 16
  • [4] MEK activation is associated with a molecular subgroup in high grade serous ovarian cancer
    McCabe, Nuala
    Gourley, Charlie
    McGavigan, Andrena
    Michie, Caroline .
    McGivern, Niamh
    Churchman, Michael
    O'Brien, Eamonn J.
    Hill, Laura
    Davison, Timothy S.
    Williams, Alistair
    McCluggage, Glenn
    Keating, Karen E.
    Harkin, Denis P.
    Kennedy, Richard D.
    CANCER RESEARCH, 2016, 76
  • [5] NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
    Fernandez, Marta Llaurado
    Hijmans, E. Marielle
    Gennissen, Annemiek M. C.
    Wong, Nelson K. Y.
    Li, Shang
    Wisman, G. Bea A.
    Hamilton, Aleksandra
    Hoenisch, Joshua
    Dawson, Amy
    Lee, Cheng -Han
    Bittner, Madison
    Kim, Hannah
    DiMattia, Gabriel E.
    Lok, Christianne A. R.
    Lieftink, Cor
    Beijersbergen, Roderick L.
    de Jong, Steven
    Carey, Mark S.
    Bernards, Rene
    Berns, Katrien
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (12) : 1862 - 1874
  • [6] Mutations in low-grade serous ovarian cancer and response to BRAF and MEK inhibitors
    Moujaber, Tania
    Etemadmoghadam, Dariush
    Mapagu, Cristina
    Kennedy, Catherine
    Chiew, Yoke-Eng
    Kan, Casina
    Nevins, Nikilyn
    Srirangan, Sivatharsny
    Fereday, Sian
    Traficante, Nadia
    Bowtell, David
    Balleine, Rosemary
    Harnett, Paul
    deFazio, Anna
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer
    Mert, Ismail
    Chhina, Jasdeep
    Allo, Ghassan
    Dai, Jing
    Seward, Shelly
    Carey, Mark S.
    Llaurado, Marta
    Giri, Shailendra
    Rattan, Ramandeep
    Munkarah, Adnan R.
    GYNECOLOGIC ONCOLOGY, 2017, 146 (02) : 319 - 326
  • [8] Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer
    McNamara, Blair
    Greenman, Michelle
    Demirkiran, Cem
    Mutlu, Levent
    Hartwich, Tobias
    Bellone, Stefania
    Manavella, Diego
    Zipponi, Margherita
    Yang-Hartwich, Yang
    Yang, Kevin
    Ratner, Elena
    Schwartz, Peter
    Santin, Alessandro
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S36 - S36
  • [9] MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype
    Gershenson, David M.
    Gourley, Charlie
    Paul, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3731 - +
  • [10] In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer
    McNamara, Blair
    Demirkiran, Cem
    Bellone, Stefania
    Mutlu, Levent
    Zipponi, Margherita
    Verzosa, Miguel S.
    Harold, Justin
    Hartwich, Tobias M.
    Altwerger, Gary
    Ratner, Elena
    Huang, Gloria
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Schwartz, Peter E.
    Dottino, Peter
    Santin, Alessandro D.
    CANCER RESEARCH, 2023, 83 (07)
12345